11
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T22288 | (1E)-CFI-400437 dihydrochloride | CFI-400437 dihydrochloride | PLK |
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor. | |||
T7384 | Ocifisertib(CFI-400945 free base) | PLK | |
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM). | |||
T14927 | Centrinone | LCR-263 | PLK , Aurora Kinase |
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). | |||
T1843 | XMD8-92 | ERK , BMI-1 , Epigenetic Reader Domain | |
XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM). | |||
T14926 | Centrinone-B | LCR-323 | Aurora Kinase |
Centrinone-B (LCR-323) is a potent and highly selective inhibitor of PLK4 (Ki: 0.59 nM). | |||
T63318 | CFI-400437 | ||
CFI-400437 is an ATP-competitive PLK4 inhibitor (IC50: 0.6 nM) and is an indolequinone derivative. | |||
T78728 | SP27 | PROTACs | |
SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1]. | |||
T73471 | YLT-11 | ||
YLT-11 is a potent, selective, and orally active inhibitor of polo-like kinase 4 (PLK4), exhibiting dissociation constant (Kd) values of >10000 nM for PLK1, 653 nM for PLK2, >10000 nM for PLK3, and 5.2 nM for PLK4, respe... | |||
T82385 | FMF-06-098-1 | PROTACs | |
FMF-06-098-1 is a multitargeted depressant capable of promoting the degradation of a wide array of kinases, including AAK1, ABL2, AURKA, AURKB, BUB1B, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDK6, CDK7, CDK9, CHEK1, CSNK1D... | |||
T19664 | ON1231320 | GBO-006 | Apoptosis , PLK |
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor. | |||
T74644 | DB0614 | ||
DB0614 (Example 21) is a bifunctional compound designed for the targeted degradation of kinases, effectively breaking down a wide array of kinases including AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK... |